TCL1A and myeloid sarcoma: More recently, a genome-wide association study (GWAS) discovered genetic variants localized in the region of TCL1A gene loci appeared to influence the risk of MS-AEs in patients undergoing AIs treatment [15], suggesting that this gene plays a role for MS toxicity.